Title : Pharmacological advancement in pulmonary arterial hypertension treatment - Contribution of treprostinil dry-powder formulation
Abstract:
Pulmonary Arterial Hypertension (PAH) is still a devastating illness with substantial morbidity and death outcomes. Taking into account that the disease advances quickly for many patients, and is commonly associated with severe clinical symptoms, new treatment options are still required. Treprostinil, a prostacyclin analog in a form of inhalation powder, was recently approved by the FDA for adults with Pulmonary Arterial Hypertension (PAH, WHO Group 1) and pulmonary hypertension associated with interstitial lung disease (PH-ILD, WHO Group 3) to improve exercise ability. This is the first-in-class prostacyclin dry-powder formulation, which yields uniform, free-flowing particles designed to enhance deep-lung delivery via an easy-to-use, low-effort device requiring less inspiratory effort. The approval of treprostinil dry-powder was primarily based on findings from the phase 3 INSPIRE trial, which evaluated patients who were naive to treprostinil, as well as those transitioning to new formulation from nebulized treprostinil. Treprostinil dry-powder was shown to be safe and well-tolerated regardless of a patient’s previous exposure to treprostinil, thus providing a new quality in treatment of PAH and PH-ILD, especially in patients with limited inspiratory flows or lung capacity. Given the previous facts, the main objectives of this presentation will be to clarify the pharmacological properties of treprostinil dry-powder, including pharmacodynamics, pharmacokinetics, indications, and contraindications for use, adverse drug reactions, as well as the most important drug interactions. This will provide a better understanding of this first-in-class dry-powder formulation for PAH, consequently helping clinicians in its suitable prescribing and adequate clinical use.
